Domestic migraine drug market expected to grow

Published: 2003-08-08 06:58:00

Updated: 2003-08-08 06:58:00

Stimulated by the recent strategic alliances between CJ/Yuyu Pharm and GlaxoSmithKline over the exclusive distribution of Naramig and Imigran in domestic pharmaceutical market, Korea's anti-migraine drug market is likely to grow in anticipation of generics introduction by new entrants, amidst mou...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK